Orexo AB Q2 2026 Financial Results
Orexo AB, a Swedish specialty pharmaceutical company, announced its financial performance for the second quarter of 2026. Revenue for the quarter was SEK 3.50 million, falling short of the consensus analyst estimate of SEK 5.00 million and representing a decline versus the same quarter last year. Earnings per share, both basic and diluted, were –SEK 2.92. The company recorded an EBIT loss of SEK 103.30 million and an EBITDA loss of SEK 95.10 million.
Operating expenses increased, driven by continued research and development spending and organisational changes following the divestiture of its Zubsolv business in the United States. Despite the weaker top line, Orexo reported progress in its rescue‑medication pipeline and noted heightened external interest in its AmorphOX technology, with multiple partnering discussions underway.
Looking ahead, Orexo intends to commence a pivotal clinical trial of OX640 in the fourth quarter of 2026, with results anticipated in the first quarter of 2027. The firm also plans to resubmit the New Drug Application for Izipry in the third quarter of 2026 and expects a possible FDA approval in the first quarter of 2027. To fund these initiatives and to address ongoing legal matters with the U.S. Department of Justice, the company is evaluating additional financing opportunities.